These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8828991)

  • 21. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.
    Stocchi F; Barbato L; Nordera G; Bolner A; Caraceni T
    J Neural Transm (Vienna); 2004 Feb; 111(2):173-80. PubMed ID: 14767720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical advantages of COMT inhibition with entacapone - a review.
    Gordin A; Kaakkola S; Teräväinen H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
    Brooks DJ; Sagar H;
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1071-9. PubMed ID: 12876237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Entacapone: is it useful as complimentary treatment with levodopa?].
    Burguera JA; Grandas F; Horga de la Parte JF; Luquin R; Martí F; Matías-Guiu J; Obeso JA; Kulisevsky J
    Rev Neurol; 1999 Apr 16-30; 28(8):817-34. PubMed ID: 10363328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
    Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
    Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Entacapone.
    Chong BS; Mersfelder TL
    Ann Pharmacother; 2000 Sep; 34(9):1056-65. PubMed ID: 10981253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
    Larsen JP; Worm-Petersen J; Sidén A; Gordin A; Reinikainen K; Leinonen M;
    Eur J Neurol; 2003 Mar; 10(2):137-46. PubMed ID: 12603288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bimodal administration of entacapone in Parkinson's disease patients improves motor control.
    Bet L; Bareggi SR; Pacei F; Bondiolotti G; Meola G; Schapira AH
    Eur J Neurol; 2008 Mar; 15(3):268-73. PubMed ID: 18290846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entacapone in the treatment of Parkinson's disease.
    Schrag A
    Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
    Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
    Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
    Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
    Keränen T; Gordin A; Harjola VP; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Seppälä L; Wikberg T
    Clin Neuropharmacol; 1993 Apr; 16(2):145-56. PubMed ID: 8477410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
    Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
    Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
    J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
    Myllylä VV; Sotaniemi KA; Illi A; Suominen K; Keränen T
    Eur J Clin Pharmacol; 1993; 45(5):419-23. PubMed ID: 8112370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Entacapone. A review of its use in Parkinson's disease.
    Holm KJ; Spencer CM
    Drugs; 1999 Jul; 58(1):159-77. PubMed ID: 10439935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.